x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2015 > Cachexia and Nutrition in Advanced Cancer Patients: A Multidisciplinary Approach
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Cachexia and Nutrition in Advanced Cancer Patients: A Multidisciplinary Approach

12 ESCO credits

13.03.2015  -  14.03.2015

Barcelona, Spain

CONFERENCE

Pain treatment

Description

Chairs: M. Aapro, CH - J. Herrstedt, DK - F. Strasser, CH


Cachexia and other nutritional problems are very frequent throughout the whole trajectory of advanced cancer patients, from diagnosis of incurable disease, during multimodal anticancer treatment and end-of-life.
They impact negatively both response to and toxicity of anticancer treatment, impair quality of life including, but not limited to, physical function and emotional distress, reduce survival, and increase burden to family members.

Continuous monitoring of nutritional issues by multidisciplinary teams with a sentinel role of oncologists and oncology nurses allows early and focused interventions, tacking advantage both of new emerging drugs tackling central mechanisms of cancer cachexia and multimodal treatments, such as physical activity, nutritional counselling, emotional support and others.
Embedding excellent clinical care in a state-of-art educational environment both for professionals and patients, and also integrated clinical research will further improve many relevant outcomes.

This conference focuses on multidisciplinary care of advanced cancer patients, integrating novel pharmacological and other therapeutic opportunities.

We hope that you will join us and contribute to further develop the understanding and treatment of the disease.

On behalf of the Chairs



LEARNING OBJECTIVES
• Understand the importance of detection and assessment of malnutrition, cancer cachexia and symptoms interfering with nutritional intake
• Learn about the impact of cancer cachexia on treatment effect, cancer treatment toxicity, and quality of life
• Learn about cachexia prevention, multimodal treatment options and the importance of best supportive care
• Discuss the importance of food and body image in society and culture.


MAIN TOPICS
• Malnutrition and cachexia
• New anti-cachexia drugs in advanced cancer care
• Cachexia in supportive and palliative oncological rehabilitation
• Patient-centred personalized nutrition and cachexia management
• Parental nutrition in advanced cachectic cancer patients
• Refractory cachexia, old and frail, poor performance status
• Development of the nutrition and cachexia in oncology


         
         

The Conference is
held with the support of

        
         
         

 Under the Auspices of the
European Association for
Palliative Care, EAPC Onlus

and MASCC

     
 

 

General information

ORGANISING SECRETARIAT
European School of Oncology (ESO)
Via Turati 29 - 20121
Milan, Italy

Organisation
Daniela Mengato - dmengato@eso.net

Registrations
Laura Richetti - lrichetti@eso.net


VENUE
Crowne Plaza Bercelona
Fira Palace
Av. Rius i Taulet, 1-3
Barcelona, Spain
www.crowneplaza.com/barcelonafira


SPONSORED SATELLITE SYMPOSIA

   


13 March 2015, 9:00 - Fresenius-Kabi satellite symposium
The power of nutritional support in cancer


 9:00 Introduction
M. Muscaritoli, IT
 9:05
 Nutritional modulation of chemotherapy efficacy
V. Baracos, CA  
 9:30 The role of nutritional support during radio-/chemotherapy
M. Muscaritoli, IT   
 9:55
 Benefits for cancer patients on home parenteral nutrition
J.P. Durand, FR
 10:20 Closing remarks
V. Baracos, CA
  
Symposium faculty:

Vickie Baracos, University of Alberta, CA
Jean-Philippe Durand, University Hospital COCHIN, Paris, FR
Maurizio Muscaritoli, Sapienza-Università di Roma, IT 
   



13 March 2015, 17:30 - Helsinn Healthcare satellite symposium
Therapeutic options for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

 17:30 Welcome and introduction
F. Strasser, CH         
 17:40 The emerging role of anamorelin in patients with NSCLC
K. Fearon, UK
 18:00 The role of non-pharmacological options
A. Viganò, CA
  18:20
 The importance of a multimodal approach
S. Kaasa, NO
 18:40 Discussion and conclusions
F. Strasser, CH
  
Symposium faculty:

Kenneth Fearon, University of Edinburgh, UK
Stein Kaasa, St. Olavs Hospital, Trondheim University Hospital, NO
Florian Strasser, Kantonsspital St. Gallen, CH
Antonio Viganò, McGill University, Montreal, CA



OFFICIAL LANGUAGE

The official language will be English. No translation will be provided.


BADGE
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.


INSURANCE
The organisers bears no responsibility for ontoword events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.




Faculty list


CHAIRS

M.S. Aapro, Clinique de Genolier, Geneve, CH
J. Herrstedt, Odense University Hospital, Odense, DK
F. Strasser, Kantonsspital St. Gallen, CH



INVITED FACULTY
S. Antoun, Institut Gustave Roussy, Paris, FR
J. Arends, KTB Tumor Biology Center, Freiburg, DE
J.M. Argilés, University of Barcelona, ES
V. Baracos
, University of Alberta, CA
D. Blum, Kantonsspital St. Gallen, CH
F. Bozzetti, University of Milan, IT
F. Creamer, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, UK
K. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, UK
I. Gioulbasanis, University of Thessaly School of Medicine, Larissa, GR
J. Hopkinson, Cardiff School of Nursing and Midwifery Studies, College of Biomedical and Life Sciences, Cardiff University, UK
N. Johns, University of Edinburgh, UK
S. Kaasa, St. Olavs Hospital, Trondheim, NO
B. Laird, University of Edinburgh, UK
M. Maddocks, Kings College London, UK
L. Oldervoll, Norwegian University of Science and Technology, Trondheim, NO
C. Prado, University of Alberta, CA
P. Ravasco, University of Lisbon, PT
J. Reid, Queen’s University Belfast, UK
A. Schols, Maastricht University, NL
R. Simanek, Medical University, Vienna, AT
T. Skeidsvoll Solheim, Norwegian University of Science and Technology, Trondheim, NO
U. Wedding, Friedrich-Schiller-Universität Jena, DE
A. Wilcock
, Nottingham City Hospital, UK



.

Programme


13 March

   
 9:00
 Sponsored satellite symposium (For further details, please see the Information page).
10:30
  Coffee break
OPENING SESSION AND WELCOME
 11:00 Welcome to Barcelona - translational cachexia research
J.M. Argilés, ES

11:06
  Relevance of poor performance status in oncology       
S. Kaasa, NO
11:14
 Demand for nutritional and anti-cachexia interventions
M. Aapro, CH
11:22 Patient-centered personalized advanced cancer care       
F. Strasser, CH
ADVANCED CANCER PATIENTS AT RISK FOR MALNUTRITION AND CACHEXIA
Chairs: S. Kaasa, NO - A. Schols, NL
 11:30 Genetics of cachexia                   
N. Johns, UK
11:45
 High risk groups for malnutrition and cachexia       
P. Ravasco, PT  
 12:00  Effect of palliative cancer care on malnutrition and cachexia
S. Kaasa, NO
 12:15  Adverse effects of anticancer drugs on nutritional intake
M.S. Aapro, CH
 12:30 Anticancer drug toxicity on muscle mass and function       
S. Antoun, FR
 12:45 Discussion
 13:00 Poster session and standing lunch in poster area
EDUCATIONAL SYMPOSIUM
INTEGRATING OF NUTRITION AND CACHEXIA CARE IN PATIENT TREATMENT TRAJECTORIES

Chairs: D. Blum, CH - T. Skeidsvoll Solheim, NO
 14:00  Identification of cancer patients at risk for malnutrition in daily oncology practice                  
K. Fearon, UK
 14:20 Role of multi-professional guidelines in changing practice   
J. Arends, DE
 14:40 Nutrition and cachexia in integrated oncology and palliative care   
F. Strasser, CH
 15:00 Discussion
 15:30 Coffee break
IMPACT OF MALNUTRITION AND CACHEXIA ON ANTICANCER TREATMENT PRACTICE
Chairs: S. Antoun, FR - N. Johns, UK  
 16:00 Routine sarcopenia-monitoring in cancer radiology       
C. Prado, CA
 16:15  Sarcopenia and multimodal/surgical anticancer treatment outcomes   
F. Creamer, UK
 16:30 Combined impact of sarcopenia and cachexia on survival   
V. Baracos, CA
 16:45 Cachexia-based anticancer treatment practice tool       
D. Blum, CH 
 17:00   
Abstract presentation        
 17:15  Discussion
 17:30 Sponsored satellite symposium (For further details, please see the Information page).
 19:00
 Welcome reception
   
   

14 March

 
INTEGRATION OF PUBLISHED NEW ANTI-CACHEXIA DRUGS IN ADVANCED CANCER CARE   
Chairs: K. Fearon, UK - F. Strasser, CH
 9:00 Impact of effective anticancer treatment on cachexia       
J. Herrstedt, DK
9:15
 Anamorelin                       
K. Fearon, UK
9:30
 Anti-myostatin                   
F. Strasser, CH
9:45
 SARMs                       
V. Baracos, CA
10:00
 Abstract presentation
10:15
 Discussion
10:30
 Coffee break
CACHEXIA IN SUPPORTIVE AND PALLIATIVE ONCOLOGICAL REHABILITATION   
Chairs: V. Baracos, CA - A. Wilcock, UK  
 11:00 Emerging evidence for multimodal cachexia management   
B. Laird, UK
11:20
 Physical activity interventions               
M. Maddocks, UK
11:40
 Modern individualized re-habilitation for advanced cancer   
L. Oldervoll, NO
12:00
 Discussion
EDUCATIONAL SYMPOSIUM
PATIENT-CENTRED PERSONALIZED NUTRITION AND CACHEXIA MANAGEMENT   

Chairs: J.M. Argilés, ES - P. Ravasco, PT
 12:10 Clinical characterisation of cachectic patients           
I. Gioulbasanis, GR
 12:30
 Individualized nutrition interventions           
P. Ravasco, PT
 12:50
 Nutritional phenotyping lung cancer patients           
A. Schols, NL
 13:10 Discussion
 13:30  Poster session and standing lunch in poster area
DEBATE ON PARENTERAL NUTRITION IN ADVANCED CACHECTIC CANCER PATIENTS   
Chairs: I. Gioulbasanis, GR - J. Hopkinson, UK  
 14:30
 Setting the scene: evidence from literature and survey       
R. Simanek, AT
 14:45 Pro parenteral nutrition                   
F. Bozzetti, IT
 15:00
 Con parenteral nutrition               
J. Arends, DE
 15:15 Discussion
VULNERABLE PATIENTS: REFRACTORY CACHEXIA, OLD AND FRAIL, POOR PERFORMANCE STATUS   
Chairs: B. Laird, UK - J. Arends, DE
 15:30 Eating-related distress of patients and family members       
J. Hopkinson, UK
 15:45 Physical activity interventions in palliative intention       
A. Wilcock, UK
 16:00
 Multimodal management of old, multi-morbid patients       
M.S. Aapro, CH
 16:15 Pharmacological symptom relief in refractory cachexia       
T. Skeidsvoll Solheim, NO
 16:30
 Nutritional counselling in palliative intention           
J. Reid, UK
 16:45 Discussion
 17:00 Coffee break
DEVELOPMENT OF THE NUTRITION AND CACHEXIA FIELD IN ONCOLOGY   
Chairs: M.S. Aapro, CH - J. Herrstedt, DK - F. Strasser, CH
 17:15 Integrating cachexia staging and outcomes in EORTC trials   
U. Wedding, DE
 17:30
 Discussion
 17:45
 Closing remarks   

A/V RECORDING DURING THE CONFERENCE IS PROHIBITED

.

Abstract


ABSTRACT SUBMISSION

DEADLINE FOR SUBMISSION: 15 FEBRUARY 2015


New abstracts that will be sent within 15 February 2015 will be assessed for poster presentation at the conference ONLY, or for publication only in the event dedicated website.

Participants are invited to submit an abstract on cachexia and nutrition in advanced cancer patients in one of the following categories:

• Screening, assessment and classification
• Oral, enteral, parenteral nutrition
• Multimodal interventions
• Anti-cachexia drugs
• Impact of malnutrition/cachexia on cancer care
• Cancer rehabilitation
• Education

Instructions:

• Accessing the abstract submission system, you will be asked to login to the ESO website with your account details (if you are not yet registered, please create an ESO account);
• The abstract should be limited to 2500 characters, not including the title;
• The title should be in lower case letters;
• Names of research groups should appear in the title, not in the authors’ list;
• Tables and images are not accepted.
• For each author you should indicate First Name, Family Name, email address, affiliation(s). As all communications will be made by email, please make sure you provide correct addresses;
• List the authors’ affiliations and combine them with the authors. The same affiliation should be entered only once.
• The first author should be indicated (first author = corresponding author and presenter);
• The first author (i.e. corresponding author and presenter) will receive an acknowledgement of receipt and all subsequent communication by e-mail;
• For abstracts accepted for presentation (oral or poster), the first author will be the presenting author and is requested to register and participate in the Conference.
• It is the responsibility of the submitter to ascertain whether all authors are aware of the content of the abstract before submission is made.
• You will be able to apply changes to the submitted text until ESO validates your abstract (please refer to your dashboard on the ESO website). Once the text has been validated, no further modifications will be accepted.

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by 1 March 2015 to the first author who will be required to register to the conference.

For more information, please contact: dmengato@eso.net